Clinical Trial Update: A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma [Phase 3]

View source ↗

Summary

A multicenter, single-arm, open-label safety study evaluating lenalidomide plus dexamethasone in patients with previously treated multiple myeloma; results were…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Revlimid (lenalidomide)

Snippet

Sponsor: Celgene Corporation | Conditions: Multiple Myeloma | Phase 3 | Status: COMPLETED | Results posted: 2012-03-14